Progesterone could become tool versus brain cancer

by Quinn Eastman
Progesterone could become tool versus brain cancer
Glioblastoma is the most common and the most aggressive form of brain cancer in adults, with average survival after diagnosis of around 15 months.

(Medical Xpress)—The hormone progesterone could become part of therapy against the most aggressive form of brain cancer. High concentrations of progesterone kill glioblastoma cells and inhibit tumor growth when the tumors are implanted in mice, researchers have found.

The results were recently published in the Journal of Steroid Biochemistry and Molecular Biology.

Glioblastoma is the most common and the most aggressive form of in adults, with average survival after diagnosis of around 15 months. Surgery, radiation and chemotherapy do prolong survival by several months, but targeted therapies, which have been effective with other forms of cancer, have not lengthened survival in patients fighting .

The lead author of the current paper is Fahim Atif, PhD, Assistant Professor of Emergency Medicine at Emory University. The findings with glioblastoma came out of Emory researchers' work on progesterone as therapy for traumatic brain injury and more recently, stroke. Atif, Donald Stein and their colleagues have been studying progesterone for the treatment of for more than two decades, prompted by Stein's initial observation that females recover from brain injury more readily than males. There is a similar tilt in glioblastoma as well: primary glioblastoma develops three times more frequently in males compared to females.

This video is not supported by your browser at this time.
Emory neuroscientist Donald Stein finds further vindication in his long-held belief that progesterone is more than just a female hormone.

These results could pave the way for the use of progesterone against glioblastoma in a human clinical trial, perhaps in combination with standard-of-care therapeutic agents such as temozolomide. However, Stein says that more experiments are necessary with grafts of human tumor cells into animal brains first. His team identified a factor that may be important for clinical trial design: progesterone was not toxic to all glioblastoma cell lines, and its toxicity may depend on whether the p53 is mutated.

Atif, Stein, and colleague Seema Yousuf found that low, physiological doses of progesterone stimulate the growth of glioblastoma tumor cells, but higher doses kill the tumor cells while remaining nontoxic for . Similar effects have been seen with the progesterone antagonist RU486, but the authors cite evidence that is less toxic to healthy cells. Progesterone has also been found to inhibit growth of neuroblastoma cells (neuroblastoma is the most common cancer in infants), as well as breast, ovarian and colon cancers in cell culture and animal models.

More information: Fahim Atif, Seema Yousuf, Donald G. Stein, "Anti-tumor effects of progesterone in human glioblastoma multiforme: Role of PI3K/Akt/mTOR signaling," The Journal of Steroid Biochemistry and Molecular Biology, Available online 28 April 2014, ISSN 0960-0760, dx.doi.org/10.1016/j.jsbmb.2014.04.007.

add to favorites email to friend print save as pdf

Related Stories

Killer cocktail fights brain cancer

Nov 25, 2013

A novel immune-boosting drug combination eradicates brain cancer in mice, according to a study in The Journal of Experimental Medicine.

Human fat: A trojan horse to fight brain cancer?

May 01, 2014

Johns Hopkins researchers say they have successfully used stem cells derived from human body fat to deliver biological treatments directly to the brains of mice with the most common and aggressive form of brain tumor, significantly ...

Healing hormone provides hope for brain injury

Apr 24, 2013

If Don Stein were the kind of man who listened to what others said, he would have shut down his lab years ago. The Emory neuroscientist spent more than two decades investigating progesterone as a treatment ...

Recommended for you

Pain and itch may be signs of skin cancer

11 hours ago

Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study headed by Gil Yosipovitch, MD, Chairman of the Department of Dermatology ...

Genetics of cancer: Non-coding DNA can finally be decoded

15 hours ago

Cancer is a disease of the genome resulting from a combination of genetic modifications (or mutations). We inherit from our parents strong or weak predispositions to developing certain kinds of cancer; in addition, we also ...

User comments